Business Context and Reporting Period
PharmaCyte Biotech, Inc. filed this Form 8-K on August 2, 2021, to announce preliminary unaudited financial results for the fiscal year ended April 30, 2021. The company is a biotechnology firm focused on developing treatments, including for pancreatic cancer.
Key Financial Metrics
| Metric | Fiscal Year Ended April 30, 2021 | Fiscal Year Ended April 30, 2020 |
|---|---|---|
| Net Loss | Approx. $3.6 million | Approx. $3.8 million |
| Loss Per Share (Basic & Diluted) | Approx. $2.45 | Approx. $4.23 |
| Cash on Hand (as of April 30, 2021) | Approx. $2.2 million | N/A |
The filing does not provide specific values for revenue, operating margins, debt levels, or cash flow from operations.
Material Changes
- Net Loss Reduction: The net loss decreased by approximately $200,000 compared to the prior fiscal year.
- Loss Per Share Improvement: Loss per share improved significantly from $4.23 to $2.45, attributed to changes in the weighted average number of shares outstanding.
Outlook, Risks, and Contingencies
Management highlighted several critical risks and forward-looking factors that could materially affect future results:
- Clinical Hold: The company faces a clinical hold on its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) regarding a trial for locally advanced and inoperable pancreatic cancer. Progress depends on satisfactorily addressing FDA issues.
- Capital Needs: The company must raise necessary capital to fund ongoing operations.
- Stock Listing: There is uncertainty regarding the ability to up-list common stock to a national securities exchange and maintain such listing.
- Partnerships: Future success may depend on finding partners to supplement capabilities and resources.
The financial data presented is preliminary and subject to final adjustments upon completion of financial closing procedures.
Investor Verification Checklist
- Verify the final audited financial results once the fiscal year closing procedures are complete.
- Monitor the status of the FDA clinical hold on the pancreatic cancer IND application.
- Assess the company's progress in raising capital given the $2.2 million cash position.
- Review upcoming filings (10-K/10-Q) for detailed revenue and expense breakdowns not included in this 8-K.